The global blood-based neurodegenerative biomarker diagnostics market was valued at $1.1 billion in 2025 and is projected to surge to $5.8 billion by 2034, expanding at a robust compound annual growth rate (CAGR) of 20.3% during the forecast period 2026-2034. This exceptional growth trajectory is being fueled by a convergence of scientific breakthroughs, regulatory momentum, and urgent unmet clinical need in diagnosing neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS) through a minimally invasive blood draw rather than costly and burdensome cerebrospinal fluid (CSF) lumbar punctures or positron emission tomography (PET) imaging. In 2026, the market is already witnessing a step-change transition from research-use-only (RUO) assays to laboratory-developed tests (LDTs) and cleared in-vitro diagnostic (IVD) devices, with regulatory authorities in the United States, Europe, and Japan accelerating review timelines for plasma biomarker platforms.https://researchintelo.com/report/blood-based-neurodegenerative-biomarker-diagnostics-market